On August 26, McKesson rose 3.02% in regular trading, trading at $900.22 per share, with turnover of $405 million.

On the news front, McKesson announced it will acquire Precision Medicine Group for approximately $2.25 billion. Upon completion, the acquired business will be reported within McKesson's Oncology and Multispecialty business segment, a strategic move expected to deepen the company's service capabilities in the oncology space.

The acquisition comes on the heels of strong fiscal Q1 2027 results reported earlier this month. Adjusted EPS of $9.93 beat consensus estimates by 4.09%, representing a 20.22% year-over-year increase from $8.26. Revenue of $105.38 billion also exceeded the $103.88 billion estimate. Management simultaneously raised its full-year adjusted EPS guidance to $44.20-$45.00, above the prior range of $43.80-$44.60. Wall Street sentiment remains constructive, with Barclays raising its price target to $1,000, BofA Securities to $1,050, and Citigroup to $1,000, all maintaining bullish ratings.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)